About HebeCell
HebeCell is a Healthcare company based in Natick (United States) founded in 2016 by Allen Feng. NK cell therapeutics for cancer and autoimmune diseases are developed. HebeCell has raised $53 million across 1 funding round from investors including Beijing Jiakesi drug development. Its chief executive, as recorded, is John Lu. HebeCell offers products and services including ProtoNK Cells, Cryopreserved Cells, Custom-Made Cell Production, and Contract Manufacturing Service. Its focus areas include Life Sciences, Cell Therapy, Adoptive Cell Therapy and NK-Cell. Its legal entity is HebeCell Corp. Its competitors include Revolution Medicines, Blueprint Medicines and Syndax; 3 of its 3 listed competitors have raised funding.
Company details
HebeCell was founded in 2016 and is based in Natick, United States. Operations focus on the biotechnology sector, where NK cell therapeutics are developed using a proprietary 3D-pluripotent stem cell platform. These therapies target cancer, viral infections, and autoimmune diseases. The companys activities center on advancing cell-based treatments for multiple indications through research and development.
- Headquarters Natick, United States
- Founders Allen Feng
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website hebecellcorp.com
- Social LinkedIn
- Legal Name Hebecell Corp
- Total Equity Funding$53M (USD)
in 1 rounds
- Latest Funding Round$53M (USD), Series A
Aug 2021
- Investors
Products & Services of HebeCell
HebeCell offers a comprehensive portfolio of products and services, including ProtoNK Cells, Cryopreserved Cells, Custom-Made Cell Production, and Contract Manufacturing Service.
Produces scalable natural killer cells for cancer treatment applications.
Provides preserved cells for research and therapeutic use.
Offers tailored cell production using customer or in-house lines.
Handles large-scale cell production for clinical and research needs.
Funding Insights of HebeCell
HebeCell has successfully raised a total of $53M through 1 strategic funding round. The most recent funding activity was a Series A round of $53 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $53M
- Total Rounds 1
- Last Round Series A — $53M
- First Round $53M
(Aug 2021)
- Investors Count 1
All 1 funding rounds of HebeCell with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2021 | $53M | Series A | – | Beijing Jiakesi drug development | – |
1 investors in total: 1 institutional.
Investors in HebeCell
HebeCell has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Beijing Jiakesi drug development.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Small molecule therapeutics for cancer treatment are developed. | 2015 | jacobiopharma.com | Beijing, China |
Investor details for HebeCell
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of HebeCell
7 people are tracked at HebeCell (5 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Allen Feng | Founder | Leadership |
John Lu | CEO | Leadership |
Lily Tang | VP of Finance & Administration | Leadership |
Lily Tang, CPA, CGMA | VP, Finance and Administration | Leadership |
ShiYu Wang | R&D Director | Leadership |
Miaoyun Zhang | Manager of iNK Bioprocessing | Team |
Victoria Farrell | Senior Scientist | Team |
Complete people profiles for HebeCell
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of HebeCell
2 dated milestones of HebeCell across 5 years, from founding to its latest funding, stage changes and deals.
- Founded HebeCell is founded.
- Funding First funding round of $53.0M.
Competitors of HebeCell
HebeCell has 3 listed competitors in our database, 3 of them funded. They include Revolution Medicines, Blueprint Medicines and Syndax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. |
Detailed competitors of HebeCell
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of HebeCell
Websites that share an audience with HebeCell (hebecellcorp.com).
Websites whose visitors overlap most with HebeCell. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| qhpcapital.com | 100% | #4,330,266 | View details |
Top companies in Cell Therapy
3 companies that operate in the same segment as HebeCell (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hebecell
Complete news archive for HebeCell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HebeCell
HebeCell was founded in 2016 and raised its 1st funding round 5 years after it was founded.
HebeCell is headquartered in Natick, United States. It is registered at Natick, Massachusetts, United States.
John Lu is the CEO of HebeCell, as recorded in our data.
HebeCell is a funded company, having raised a total of $53M across 1 funding round to date. The company's 1st funding round was a Series A of $53M, raised on Aug 2021.
HebeCell was founded in 2016 and is based in Natick, United States. Operations focus on the biotechnology sector, where NK cell therapeutics are developed using a proprietary 3D-pluripotent stem cell platform. These therapies target cancer, viral infections, and autoimmune diseases. The companys activities center on advancing cell-based treatments for multiple indications through research and development.
HebeCell's top competitors include Syndax, Revolution Medicines and Blueprint Medicines.
HebeCell offers ProtoNK Cells, Cryopreserved Cells, Custom-Made Cell Production, and Contract Manufacturing Service.
HebeCell has 1 investor. Key investors include Beijing Jiakesi drug development.
HebeCell operates through Hebecell Corp.